Gilead’s sofosbuvir for hepatitis C meets primary endpoint in fourth pivotal Phase 3 study
19 February 2013 | By Gilead Sciences
Topline results from the Phase 3 FUSION study...
List view / Grid view
19 February 2013 | By Gilead Sciences
Topline results from the Phase 3 FUSION study...
8 February 2013 | By
Gilead Sciences, Inc. announced that it has completed its acquisition of YM BioSciences Inc...
4 February 2013 | By Gilead Sciences, Inc.
Topline results from two Phase 3 studies...
24 January 2013 | By Gilead Sciences
“We are pleased to move TAF into Phase 3 clinical research...”
7 January 2013 | By Gilead Sciences
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...
12 December 2012 | By Gilead Sciences
Gilead Sciences and YM BioSciences announced that the companies have signed a definitive agreement...
10 December 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that its Board of Directors has approved a two-for-one stock split...
27 November 2012 | By Gilead Sciences, Inc.
Gilead Sciences announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread®...
27 November 2012 | By Gilead Sciences
Gilead Sciences announced topline results from the Phase 3 POSITRON study...
15 November 2012 | By Gilead Sciences
STaR study findings support Complera as an important single tablet regimen option...
15 November 2012 | By Gilead Sciences
Two-year results announced ...
31 October 2012 | By Gilead Sciences
Data support tenofovir alafenamide fumarate as component of future single tablet HIV regimens...
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
2 August 2012 | By Gilead Sciences, Inc.
Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into agreements...
24 July 2012 | By Gilead Sciences, Inc.
Full clinical trial results from a pivotal Phase 3 study...